P53 TÜMÖR SÜPRESOR GENİ

İ. Park M: Oncogencs, "The Genetic Basis of Humarı Can-cer, editörler: Vogelstein B, Kinzleı* KW, McGraw Hill, New York(1998)", sayfa: 205.
2. Feai'on ER: Tutııor Supressur Gcnes, "The Genelic Basis of Human Caııcer, editörler: Vogelstein B, Kilizler KW, McGraw Hill, New York (1998)", sayla 229.
3. Ktıudson AGJR: Mııtation and caııcer: Statistieal study of relinoblastorna. Proc Natl Acad Sci USA 68:820 (1971).
4. Linzeı Dİ, Mallzman W, Lcvine AJ: The SV4Ü A gene is rcquired for the produetion of a 54,000 MW cellular tümör anligen. Virology 98: 308 (1979)
5. Baker SJ, Fcaron ER, Nigro JM, Hamiîlon SR, Preisin-ger AC, Jessup JM, vaııTuincn P, Ledbetter DH, Barfcer DF, Nakamura Y: Chromusoıııe 17 deictions and p53 gene mulations in coloreetal carcinomas. Science 244:217 (1989)
6. Haİnaut P: Tumor-spesific mutation.s in p53: the-acid test. NatMed 8:21 (2002).
7. On Line Mendelian Inheritance in Man (Iıttp://www3. ncbi.nlm.riili.gov/Omim): TU MOR PROTEİN p53; TP53 (191170).
8. Malkin D: The Li-Fraumcni Syndrome, "The Genetic Basis of Human Cancer, editörler: Vogelstein B, Kinzier KW, McGravv Hill,New York(199S)", sayfa: 393.
9. Soengas MA, Capodiecl P, Polsky D, Mora J, Estetler M, Opilz-Araya X, McCombie R, Herman )G, Gcrald WL, Lazcbtıik YA, Cordon-Cardo C, Lowc Sc: Inaclivation ol the apoptosis cffector Apaf-I in malignant melanoma. Nature 409:207 (2001).
10. Fodde R, Smits R: A matter of dosage. Science 298: 761 (2002).
11. Venkaîachalam S, Tyner SD, Pickering CR, Boiey S, Re-cio L. Frcnclı JE, Doııehowcr LA: Is p53 haplomsuffici-ent for Cumor «.uppression? lmplications for the p53+/-nıouse model in carcinogenily testing. Toxico! Pathol 29 Suppl:147 (2001).
12. Blagosklonny MV: p53 from complexity lo simplicity: mutant p53 stabilizalion, gain of funetion, and dominanl-negativeeffect.FASEBJ 14:1901 (2000).
13. Harris CC, Holialcin M: Clinical implîcaüons of the p53 tumor-suppressorgcne. N Engl i Med 329:1318 (1993).
14. Ozlurk M: p53 mutation in hepatocellular caremoma af-tar af!atoxin cxposure. Lancet 338:1356 (1991).
15. Li FP, Fraıımcui Jf J: Soft lissue sarcoıııas, bj'cast caııcer and other neoplasms: A familial cancer syndrome? Ann Intcrn Med 71:747 (1969).
16. Bell, DW, Varley JM, Szydlo TE. Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verseüs SJ, Issei-bachcr KJ, Franmeni JF, Birch JM, Li FP, Garber JE, Haber DA. Helerozygous germ line hCHK2 mulations in Li-Fraumeni syndrome. Science 286: 2528 (1999).
17. IARC TP53 Database (hltn://www.iarc.fr/p53)
18. Andersson S, Rylander E, Strand A, Sallstrom J, Wilan-der E: The significance of p53 codon 72 polymorphism for the devclopment of cervical adenocarcİnomas. Br J Cancer 85:1153 (2001).
19. Levine AJ. P53: The cellular gatekeepcr for growth and division. Celi 88:323 (1997).
20. Giaccia AJ, Kastan MB: The complexity of p53 modula-tion: emerging patterns from divergent signals. Gene Dev 12:2973 (1998).
21. Ryan KM, Phillips AC, Vousden KH: Regulation and funetion of the p53 tumor suppressor protein. Curr Opin
Celi Biol 13:332 (2001). 1 25
P53 T ü m ö r Süpresör Geni
22. Canman CE, Lira DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD: Acti-vation of the ATM kinase by ionizing radiation antl phosphorylation of p53. Science 281:1677 (1998).
23. Linke SP, Claı-kin KC, DiLeonardo A, Tsou A, Wahl GM: A revcrsible, p53-dcpendent GÜ/G1 celi-cyclc ar-rest induced by ribonuclcotide depîetİon in the absenee of detecteabîe DNA damagc. Genes Dev 10: 934 {i 996).
24. Dreyfus DH, Nagasawa M, Kelleher CA, Gelfand EW: Stabte expression of Epstein-Baır virüs BZLF-İ-encoded ZEBRA protein aclivaies p53-dcpendent transcription in human Jurkat T-lymphobiastoid celis. Blood 96:625 (2000).
25. Kamtjo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Shcrr CJ: Functiotıal and physical interactions of the ARF tumor supprcssor with p53 AND Mdm2. Proc Natl Acad Sci USA 95:8292(1998).
26. El-Deiry WS, Tokino T, Velculescu PE, Lcvy DB, Par-sons, R, Trent JM, Lin D, Mercewr WE, Kinzler KW, Vogelstein B. WAFI, a potentia! mediator of p53 lumor suppression. Celi 75:817 (1993).
27. Chin PL, Moraand J, Pfcifer GP: in vivo evidencc for binding of p53 lo consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation. Onco-gcnc 15:87 (1997).
28. Rocco JW, Sidransky D: p(6(MTS-l/CDKN2/INK4a) in cancer progression. Exp Celi Rcs 264:42 (2001).
29. Rudİn CM, Thompson CB: Apoptosis and cancer: "The Genetic Basis of Human Cancer, editörler: Vogelstein B,
Kinzier KW, McGraw Hill. New York{1998)", sayfa: 193.
30. Zörnig M, Hueber A-O, Baum W, Evan G: Apoptosis re-gulators and theîr role in tıımorigcncsis. Biochİmica et Biophysica Açta 1551: F1-F37 (2001).
31. Woods DB, Vousden KH: Regulation of p53 funetion. Exp Celi Res 264:56 (2001).
32. Weill D, Maek M, Roth J, Swisher S, Proksch S, Merritt J, Nemunaitis J: Adenoviral-mediated p53 gene transfer to non-small celi lung cancer llırough endobronehial in-jcetion. Chest 118:966 (2000).
33. Land DP, Lain S: Therapculic exploitation of the p53 pathvvay. Trends Mol Med 4(Suppl):38-S42 (2002).
34. Foster BA: Pharmacological rescue of mutant p53 con-formation and funelion. Science 286: 2507 (] 999).
35. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV: A ehe-mical inhibiior of p53 Ihat proteets mice from the side ef-fects of cancer theıapy. Science 285:1733 (1999).
36. Wang H, Nan L, Yu D, Agrawal S, Zhang R: Antisense anti-MDM2 oligonucieotides as a ııovel thcrapeutic app-roach to human brcasl cancer: tn vitro and in vivo aetivi-ties and mechanisms. Clin Cancer Res 7: 3613 (200İ).
37. Heise C, Kim DH: Replicatioıı-selceiive udertoviruses us oncolytic agenls. J Clin Invesi 105:847 (2000).
38. Hemminki A: From molecular changes to customised therapy. Eur J Cancer 38:333 (2001).